Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.
Financial Results:
Neuland Laboratories Ltd reported Revenues for Q1FY24 of ₹363.00 Crores up from ₹221.00 Crore year on year, a rise of 64.25%.
Total Expenses for Q1FY24 of ₹282.00 Crores up from ₹209.00 Crores year on year, a rise of 34.93%.
Consolidated Net Profit of ₹62.00 Crores up 520.0% from ₹10.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹48.23, up 520.72% from ₹7.77 in the same quarter of the previous year.
*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.
*The presented data is automatically generated. It may occasionally generate incorrect information.